Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

D-Dimer Improves Risk Prediction of Venous Thromboembolism in Patients with Multiple Myeloma

Kristen M. Sanfilippo, MD MPHS, Mark A Fiala, MSW, Harsha Tathireddy, MD, Dan Feinberg, Ravi Vij, MD MBA, Brian F. Gage, MD MSc

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142762

Published: 2020

Journal Articles

Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data

Reyka G Jayasinghe, PhD, Lijun Yao, MS, Beena Thomas, Swati S Bhasin, PhD, Nicolas Fernandez, PhD, David E. Avigan, MD, Taxiarchis Kourelis, MD, Madhav V. Dhodapkar, MD, Ravi Vij, MD MBA, Shaadi Mehr, PhD, Mark Hamilton, PhD, Hearn Jay Cho, MD PhD, Daniel Auclair, Sacha Gnjatic, Li Ding, PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-143256

Published: 2020

Journal Articles

Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142205

Published: 2020

Journal Articles

The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant

Justin A King, Mark A Fiala, BS, CCRP, Daniel R Kohnen, Tanya M Wildes, MD, Keith Stockerl-Goldstein, Ravi Vij, MD MBA

Blood (2016) 128 (22): 3563.

https://doi.org/10.1182/blood.V128.22.3563.3563

Published: 2016

Journal Articles

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Mark A Fiala, BS, CCRP, Jesse Keller, MD, Jeevan Sekhar, MD, Connie Ceriotti, RN, BSN, Camille N. Abboud, MD, John F DiPersio, MD PhD, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Keith Stockerl-Goldstein, Ravi Vij, MD MBA

Blood (2016) 128 (22): 3329.

https://doi.org/10.1182/blood.V128.22.3329.3329

Published: 2016

Journal Articles

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination with G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma

Armin Ghobadi, MD, Mark A Fiala, BS, CCRP, Geoffrey L. Uy, MD, Keith Stockerl-Goldstein, Ravi Vij, MD MBA, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3381.

https://doi.org/10.1182/blood.V128.22.3381.3381

Published: 2016

Journal Articles

Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

Mark A Fiala, BS, CCRP, James Dukeman, BS, Keith Stockerl-Goldstein, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Daniel Auclair, PhD, Ravi Vij, MD MBA

Blood (2016) 128 (22): 2349.

https://doi.org/10.1182/blood.V128.22.2349.2349

Published: 2016

Journal Articles

The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

Mark A Fiala, BS, CCRP, James Dukeman, BS, Keith Stockerl-Goldstein, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Ravi Vij, MD MBA

Blood (2016) 128 (22): 2350.

https://doi.org/10.1182/blood.V128.22.2350.2350

Published: 2016

Journal Articles

Subgroup Analysis of US Patients in Preamble, an Ongoing Multinational Observational Study in Multiple Myeloma

Ravi Vij, MD MBA, Surhud Khare, Samuel Perez, Sergey Popov, Clara Chen

Blood (2016) 128 (22): 2362.

https://doi.org/10.1182/blood.V128.22.2362.2362

Published: 2016

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

Pilar De La Puente, PhD, Abbey Jin, Micah John Luderer, BS, MS, Barbara Muz, PhD MSc, Justin A King, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2016) 128 (22): 2135.

https://doi.org/10.1182/blood.V128.22.2135.2135

Published: 2016

Journal Articles

Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients By Computational Mapping of Protein Network Disturbances

Leylah Drusbosky, PhD, Mark A Fiala, BS, CCRP, Justin A King, Ravi Vij, MD MBA, Shireen Vali, PhD, Taher Abbasi, Neeraj Kumar Singh, Ansu Kumar, Saji Gera, Christopher R. Cogle, MD

Blood (2016) 128 (22): 2099.

https://doi.org/10.1182/blood.V128.22.2099.2099

Published: 2016

Journal Articles

Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood

Barbara Muz, PhD MSc, Pilar De La Puente, PhD, Justin A King, Daniel R Kohnen, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2016) 128 (22): 2076.

https://doi.org/10.1182/blood.V128.22.2076.2076

Published: 2016

Journal Articles

Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models

Barbara Muz, PhDMSc, Feda Azab, BPharm, Pilar De La Puente, PhD, Justin King, Micah John Luderer, BS, MS, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 2985.

https://doi.org/10.1182/blood.V126.23.2985.2985

Published: 2015

Journal Articles

Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study

Blood (2015) 126 (23): 722.

https://doi.org/10.1182/blood.V126.23.722.722

Published: 2015

Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Blood (2015) 126 (23): 4219.

https://doi.org/10.1182/blood.V126.23.4219.4219

Published: 2015

Journal Articles

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Blood (2015) 126 (23): 4201.

https://doi.org/10.1182/blood.V126.23.4201.4201

Published: 2015

Journal Articles

A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants

Brian S White, PhD, Irena Lanc, PhD, Daniel Auclair, PhD, Robert Fulton, PhD, Mark A Fiala, BS, CCRP, Justin King, Gregory Ahmann, BS, Mary Derome, MS, Elaine R Mardis, PhD, Joan Levy, PhD, Ravi Vij, MD MBA, John F. DiPersio, MD PhD, Michael Tomasson, MD

Blood (2015) 126 (23): 4207.

https://doi.org/10.1182/blood.V126.23.4207.4207

Published: 2015

Journal Articles

Variations in Multiple Myeloma Disease Presentation By Race

Mark A Fiala, BS, CCRP, Tanya M Wildes, MD MSCI, Michael Slade, BA, Jesse Keller, MD, Keith Stockerl-Goldstein, MD, Michael Tomasson, MD, Ravi Vij, MD MBA

Blood (2015) 126 (23): 5618.

https://doi.org/10.1182/blood.V126.23.5618.5618

Published: 2015

Journal Articles

The Association of International Staging System (ISS) Stage with Disease and Symptom Burden in Patients with Newly Diagnosed Multiple Myeloma

Mark A Fiala, BS, CCRP, Michael Slade, BA, Jesse Keller, MD, Keith Stockerl-Goldstein, MD, Michael Tomasson, MD, Tanya M Wildes, MD MSCI, Ravi Vij, MD MBA

Blood (2015) 126 (23): 2115.

https://doi.org/10.1182/blood.V126.23.2115.2115

Published: 2015

NARROW

D-Dimer Improves Risk Prediction of Venous Thromboembolism in Patients with Multiple Myeloma

Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data

Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination with G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma

Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

Subgroup Analysis of US Patients in Preamble, an Ongoing Multinational Observational Study in Multiple Myeloma

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients By Computational Mapping of Protein Network Disturbances

Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood

Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models

Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants

Variations in Multiple Myeloma Disease Presentation By Race

The Association of International Staging System (ISS) Stage with Disease and Symptom Burden in Patients with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only